Optimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of Sebetralstat
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
KalVista granted orphan drug designation for sebetralstat by MHLW
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...
Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...
Business Wire12d
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan ...
Morningstar11d
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan– – Submission advances Company’s strategic plan to address unmet ...
Nasdaq11d
KalVista Announces Orphan Drug Designation And NDA Submission For Sebetralstat In Japan
(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has ...
Stockhouse11d
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
Yahoo Finance12d
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan– – Submission advances Company’s strategic plan to address unmet needs in HAE ...
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock
JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...
Investing12d
Japan grants orphan drug status to HAE treatment
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug Designation for sebetralstat from Japan's Ministry of Health, Labour and ...